文章核心观点 Abercrombie & Fitch Co.宣布2025年9月19日举办的年度音乐节暨筹款活动The Challenge的阵容，旨在支持心理健康慈善事业，门票现已开售 [1][15] 活动信息 - 活动时间为2025年9月19日周五晚5点至11点 [7] - 活动地点在俄亥俄州新奥尔巴尼的公司全球总部 [1] - 活动有两个舞台，提供当地美食饮品、定制DIY服装、飞斧投掷、热气球骑行等体验 [5] - 普通门票175美元，含所有现场表演、无限饮食和活动T恤；VIP门票350美元，有专属舞台观景区和额外商品；虚拟门票30美元，虚拟VIP体验套装100美元，参与者可通过官网额外筹款 [6] 表演阵容 - 九次钻石认证、格莱美提名歌手Post Malone担任音乐节头牌 [2] - 开场表演有摇滚乐队Young the Giant和流行歌手Mark Ambor，还有Max McNown等艺人及DJ Axcess的支持表演 [2] 慈善合作 - 活动与GLSEN等六个慈善伙伴合作，旨在打破心理健康挑战的 stigma，创造安全校园环境并提供免费资源 [3] - 自2001年活动创办以来，公司已与客户、商业伙伴及旗下品牌筹集超5300万美元，今年活动资金将惠及六个非营利伙伴 [4] 公司介绍 - Abercrombie & Fitch Co.是全球数字主导的多渠道专业零售商，服务儿童到千禧一代，经营Abercrombie & Fitch和Hollister等品牌 [9][10] - 公司在北美、欧洲、亚洲和中东运营790多家门店，还有电商网站abercrombie.com和hollisterco.com [10]

TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. Commenting on the development, Thomas Jensen ...

New York, NY, June 27, 2025 (GLOBE NEWSWIRE) -- Mixed Martial Arts Group Limited (NYSE American: MMA) (“MMA” or the “Company”), an NYSE American listed innovator at the intersection of combat sports and digital transformation, aims to spark a global movement to redefine the way martial arts are experienced through immersive, blockchain-enabled experiences. In an era characterised by connectivity, immersion and community empowerment, MMA is creating a versatile, dual-layer platform that combines the familiar ...

Agreement Expands U.S. Business Listing Syndication by Approximately 10,000 End Users Locafy’s “AI Search Readiness” Solutions Positioned as Value-Added Upsell to Base Contract PERTH, Australia, June 27, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (NASDAQ: LCFY, “Locafy” or the “Company”), a globally recognized leader in location-based digital marketing, today announced it has entered into a strategic partnership with one of the United States’ foremost online reputation and review management platforms. Under th ...

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued the following shareholder letter from its Chief Executive Officer, Eric Poma, PhD. Dear Shareholders, 2025 has been and will continue to be a transformative year for Calidi. We have made substantial changes in the company’s leadership, its ...

文章核心观点 - 阿波罗计划于2025年8月5日公布第二季度财报，管理层将进行财务结果回顾 [1] 公司信息 - 公司是高增长的全球另类资产管理公司，在资管业务中为客户提供超额回报，通过雅典娜退休服务业务帮助客户实现财务安全 [3] - 截至2025年3月31日，公司约有7850亿美元资产管理规模 [3] 财报发布安排 - 公司计划于2025年8月5日纽交所开盘前发布2025年第二季度财报 [1] - 管理层将于美国东部时间上午8:30通过网络直播回顾财务结果，直播可在公司投资者关系网站观看，活动一小时后有回放 [1] 信息获取方式 - 公司通过网站和电子邮件列表发布收益报告，有兴趣者可注册邮件获取公司更新 [2] 联系方式 - 投资者关系全球负责人Noah Gunn，电话(212) 822-0540，邮箱IR@apollo.com [4] - 企业传播全球负责人Joanna Rose，电话(212) 822-0491，邮箱Communications@apollo.com [4]

ORLANDO, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (the “Company”) (NASDAQ: ABL), today announced that it intends to conduct an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants to purchase shares of common stock of the Company, par value $0.0001 per share (“common stock”), which warrants trade on The Nasdaq Capital Market under the symbol “ABLLW” (“public warrants”), and (ii) private placement warr ...

Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced ...

MIAMI, June 27, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, provides an update regarding the status of its interim financial statements, management’s discussion and analysis, and related CEO and CFO certificates for the three-month period ended March 31, 2025 (collectively, the “Interim Filings”).‎ As previously disclosed, the Company’s delay in completing the Interim Filings is primarily ...

GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellul ...